CIGB-258, a peptide derived from human heat-shock protein 60, decreases hyperinflammation in COVID-19 patientsMabel Hernández-Cedeño, María del Carmen Domínguez-Horta, Gerardo Guillén et al.|Cell Stress and Chaperones|2021Cited by 28
CIGB-258 immunomodulatory peptide: a novel promising treatment for critical and severe COVID-19 patientsR Venegas-Rodriguez, R Santana-Sanchez, Ruben Peña-Ruiz et al.|medRxiv|2020Cited by 7
Jusvinza, an anti-inflammatory drug derived from the human heat-shock protein 60, for critically ill COVID-19 patients. An observational studyR Venegas-Rodriguez, María del Carmen Domínguez-Horta, Anabel Serrano-Díaz et al.|PLoS ONE|2023Cited by 7
An immunomodulatory peptide CIGB-258 for the treatment of critical and severe COVID-19 patientsR. V. Rodríguez, M. C. Domínguez-Horta, Rosaura Ruiz et al.|Revista cubana de medicina militar|2020Cited by 0